Lipocine Inc. (NASDAQ:LPCN) Short Interest Down 21.0% in December

Lipocine Inc. (NASDAQ:LPCN) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 48,500 shares, a decline of 21.0% from the December 15th total of 61,400 shares. Based on an average daily volume of 29,800 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.9% of the company’s shares are sold short.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC increased its holdings in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. StockNews.com assumed coverage on Lipocine in a report on Thursday, January 9th. They set a “hold” rating on the stock. Alliance Global Partners initiated coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price for the company.

Lipocine Price Performance

Shares of NASDAQ:LPCN traded up $0.13 during trading hours on Wednesday, hitting $4.73. 28,934 shares of the company’s stock traded hands, compared to its average volume of 29,776. The firm has a market capitalization of $25.30 million, a P/E ratio of -6.22 and a beta of 1.23. The business has a fifty day moving average price of $4.94 and a 200-day moving average price of $5.05. Lipocine has a 1 year low of $3.20 and a 1 year high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, equities analysts predict that Lipocine will post -0.78 earnings per share for the current year.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.